TherapeuticsMD (NASDAQ:TXMD) Releases Quarterly Earnings Results, Beats Expectations By $6.16 EPS

TherapeuticsMD (NASDAQ:TXMD) released its quarterly earnings data on Friday. The company reported $0.04 EPS for the quarter, topping the consensus estimate of ($6.12) by $6.16, FiscalAI reports. TherapeuticsMD had a negative return on equity of 1.09% and a negative net margin of 6.64%. The company had revenue of $1.26 million during the quarter, compared to the consensus estimate of $19.77 million.

TherapeuticsMD Stock Up 2.7%

NASDAQ TXMD traded up $0.05 during trading hours on Friday, reaching $1.87. The company’s stock had a trading volume of 50,485 shares, compared to its average volume of 19,291. TherapeuticsMD has a 1 year low of $1.43 and a 1 year high of $2.95. The company has a market capitalization of $21.64 million, a price-to-earnings ratio of 93.50 and a beta of 0.68. The firm’s 50-day moving average price is $1.97 and its 200-day moving average price is $2.09.

Wall Street Analyst Weigh In

Separately, Weiss Ratings cut shares of TherapeuticsMD from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, November 4th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, TherapeuticsMD presently has a consensus rating of “Sell”.

About TherapeuticsMD

TherapeuticsMD, Inc. was a U.S. women’s health pharmaceutical company that developed and commercialized prescription products addressing contraception and symptoms associated with menopause. Its business was primarily focused on the U.S. market. The company’s products included ANNOVERA, a reusable contraceptive vaginal system; IMVEXXY, estradiol vaginal inserts prescribed for certain menopausal symptoms; and BIJUVA, an oral estradiol and progesterone treatment for moderate-to-severe vasomotor symptoms associated with menopause in eligible women.